Successful treatment of influenza A virus by oseltamivir in bone marrow transplant recipients.
INFVA is an important cause of pulmonary infections in patients receiving BMT, and is associated with considerable morbidity and mortality for a readily preventable and treatable infection. Few studies have addressed the impact of the new neuraminidase inhibitors in the prognosis of influenza after BMT. The aim of this study is to assess the impact of oseltamivir on the control of INFVA infection in BMT recipients. INFVA was screened in NPA and/or bronchoalveolar lavage using IF in all BMT recipients having respiratory symptoms. Three URTI and one associated upper and LRTI were diagnosed in three BMT recipients out of six patients admitted to the BMT unit, during eight-wk period (March and April 2008). All patients having INFVA respiratory infection were treated by oral oseltamivir 60 mg/day, begun more than 48 h after symptom onset. Respiratory symptoms disappeared within a mean of 60 h (48-96 h) of treatment. However, viral tests had remained positive for 8-39 days. Outside the initial associated URTI and LRTI, no further viral pneumonia occurred. No patient died of INFVA. Oseltamivir was well tolerated outside vomiting during the first three days of treatment in one patient. Oseltamivir appears to play an important role in the outcome of INFVA infection as well in URTI as in severe LRTI in patients receiving BMT.
Mellouli
F
F
Service d'Immuno-Hématologie Pédiatrique, Centre National de Greffe de Moelle Osseuse, Tunis, Tunisia. melloulif@yahoo.fr
Ouederni
M
M
Dhouib
N
N
Hajkacem
M A
MA
Slim
A
A
Bejaoui
M
M
D000998:Antiviral Agents / Q000627:therapeutic use*; D016026:Bone Marrow Transplantation / Q000009:adverse effects*; D002675:Child, Preschool; D005260:Female; D006801:Humans; D007223:Infant; D009980:Influenza A virus; D007251:Influenza, Human / Q000188:drug therapy* / Q000821:virology; D008297:Male; D053139:Oseltamivir / Q000627:therapeutic use*
D000998:Antiviral Agents; D053139:Oseltamivir